Skip to content
Screener

AnaptysBio, Inc. ANAB Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$41.9M-42.8%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$56.16M-84.8%
Absci Corporation logo
Absci CorporationABSI
-$33.36M-10.2%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$21.83M-41.9%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.68B+200%
Enterprise value$1.43B+169%
P/S7.2×+2.7×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net loss(52,884)(39,329)
Other comprehensive loss:
Unrealized loss on available-for-sale securities(122)(144)
Comprehensive loss$(53,006)$(39,473)
Net loss per common share:
Basic and diluted$(1.84)$(1.28)
Weighted-average number of shares outstanding:
Basic and diluted28,69130,644

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
AnaptysBio, Inc. (ANAB) reported comprehensive income (loss), net of tax, attributable to parent of -$53.01M in Q1 2026.
How has AnaptysBio, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
AnaptysBio, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 34.3% year-over-year, from -$39.47M to -$53.01M.
What is the long-term trend for AnaptysBio, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2021 to 2024), AnaptysBio, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 35.3% compound annual growth rate (CAGR), from -$58.21M to -$144.13M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It serves as a comprehensive measure of the company's financial performance beyond traditional accounting profit. Investors use this to evaluate the overall change in the company's net worth and the impact of external market factors.

Ask your AI about AnaptysBio, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude